Alnylam Pharmaceuticals (ALNY) EBIT Growth (1y) (2010 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EBIT Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 32.30% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -520.13% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 8.32% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 19.82% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 145.20% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 10.14% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1,528.74% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -563.67% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 99.51% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -94.29% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,528.74% |
| Mar 31, 2026 | 1,386.07% |
| Dec 31, 2025 | 225.26% |
| Sep 30, 2025 | 578.49% |
| Jun 30, 2025 | -133.32% |
| Mar 31, 2025 | 141.62% |
| Dec 31, 2024 | 9.66% |
| Sep 30, 2024 | -135.96% |
| Jun 30, 2024 | 121.15% |
| Mar 31, 2024 | 71.01% |
| Dec 31, 2023 | 38.28% |
| Sep 30, 2023 | 182.88% |
| Jun 30, 2023 | -19.90% |
| Mar 31, 2023 | -2.10% |
| Dec 31, 2022 | 3.06% |
| Sep 30, 2022 | -42.03% |
| Jun 30, 2022 | -31.15% |
| Mar 31, 2022 | 21.22% |
| Dec 31, 2021 | -0.17% |
| Sep 30, 2021 | 19.33% |